4Vote!
PR News Wire (Free subscription) | 10/27/2009
CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Marsha Fanucci has joined its Board of Directors. Ms. Fanucci served at Millennium Pharmaceuticals, Inc. from 2000-2009 in a number of senior positions, including chief financial officer and senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development...
5Vote!
Business Wire (Free subscription) | 10/23/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Pinnacle Financial Partners (Nasdaq: PNFP) and Marten Transport Ltd. (Nasdaq: MRTN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genzyme...
4Vote!
Medical News Today (Free subscription) | 10/22/2009
Genzyme Corporation (NASDAQ: GENZ) announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
4Vote!
Business Wire (Free subscription) | 10/20/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule. The first trial, known as...
5Vote!
Cara Community - Comments (Free subscription) | 10/15/2009
In reply to Cara's Commentary & Community Chat, Thursday, Oct. 15, 2009 : Rating Company Name Symbol 1.0 Ryanair Holdings plc RYAAY 1.4 Stericycle, Inc. SRCL 1.5 Activision Blizzard, Inc ATVI 1.6 Teva Pharmaceutical Industries Limited TEVA 1.6 Warner Chilcott plc WCRX 1.7 Cognizant Technology Solutions Corp CTSH 1.7 Express Scripts, Inc. ESRX 1.7 Gilead Sciences, Inc. GILD 1.8 Foster Wheeler AG....
Explore : Aerospace and Defense,
Altera Corporation,
Apollo Group,
Automatic Data Processing,
Baidu,
Biotechnologies,
Business,
Cable TV Networks industry,
Celgene Corporation,
Cisco Systems,
Cognizant Technology Solutions Corp.,
Comcast Corporation,
Computer industry,
Construction,
Costco Wholesale Corporation,
DENTSPLY International Inc.,
Discount Stores,
Drug Manufacturers,
Education,
Food and Beverage,
Foster Wheeler AG,
Health Industries,
Intel Corp.,
KLA-Tencor Corporation,
LAM Research Corporation,
Media,
Medical Equipment,
Microsoft Corporation,
Microsoft Yahoo,
Network Equipment,
Oracle Corporation,
Research in Motion Ltd.,
Retailers,
Ryanair Holdings plc,
Seagate Technology,
Search Engines,
Semi Conductors,
Software industry,
Starbucks Corporation,
Storage,
Symantec Corporation,
Technology,
Telecommunication,
Telecommunication Companies,
Vertex Pharmaceuticals Incorporated
5Vote!
Business Wire (Free subscription) | 10/14/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology...
4Vote!
Medical News Today (Free subscription) | 10/08/2009
Genzyme Corporation (Nasdaq: GENZ) announced that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.
4Vote!
Business Wire (Free subscription) | 10/06/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled...
4Vote!
Business Wire (Free subscription) | 10/02/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index. Genzyme is...
7Vote!
Market Wire (Free subscription) | 10/01/2009
SUGAR LAND, TX (MARKET WIRE) Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- A virus infection forced the Genzyme Corporation (NASDAQ: GENZ) to shut down the company's biopharmaceutical plant in Allston Landing, Massachusetts. The virus strain Vesivirus 2117, which was found in the site's six bioreactors, interferes with the growth of CHO cells, a component in biologic...
4Vote!
Medical News Today (Free subscription) | 09/25/2009
Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant improvement in progression free survival (PFS).
5Vote!
Business Wire (Free subscription) | 09/24/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant improvement in progression free survival (PFS)....
5Vote!
Business Wire (Free subscription) | 09/23/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products. The company is now approximately half-way through the anticipated shortage period for Cerezyme and Fabrazyme,...
5Vote!
Business Wire (Free subscription) | 09/11/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The CAMMS223 Phase 2...
Videos